Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer.

Yiting DongYixiang ZhuMinglei ZhuoXiaomin ChenYinpeng Xie Jianchun Duan Hua BaiShiguang HaoZicheng YuYuting YiYanfang GuanJie YuanXuefeng XiaXin YiJie WangZhijie Wang

Published in: Cancers (2022)

We developed Ma-bTMB, a convenient, readily available, non-invasive predictive biomarker effectively differentiates beneficiaries of ICIs therapy in advanced NSCLC, warranting future clinical trials.

Keyphrases

advanced non small cell lung cancer
clinical trial
epidermal growth factor receptor
current status
copy number
small cell lung cancer
risk factors
open label
stem cells
gene expression
dna methylation
phase iii